PIK3CA and cancer: Dactolisib (BEZ235). This drug, also called BEZ235 or NVP-BEZ235, is a reversible PI3K/mTOR inhibitor belonging to the imidazoquinoline class already tested in a variety of cancers in preclinical studies.